Search

Your search keyword '"Buzza M."' showing total 46 results

Search Constraints

Start Over You searched for: Author "Buzza M." Remove constraint Author: "Buzza M."
46 results on '"Buzza M."'

Search Results

2. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts

3. The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs

4. The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs

5. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.

6. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

7. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.

8. The Movember Foundation's GAP3 cohort

9. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

10. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer-results of a modified Delphi consensus procedure.

11. Perceived deterrents to being a plasmapheresis donor in a voluntary, nonremunerated environment

16. Development of a virtual multidisciplinary meeting framework for less common cancers.

17. Equitable Access to Genomic Molecular Testing for Australian Cancer Patients: Insights from the Victorian Precision Oncology Summit.

18. Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access.

19. Aligning organisational priorities and implementation science for cancer research.

21. The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.

22. The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs.

23. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.

24. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

25. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.

26. Janus and patchy nanoparticles: general discussion.

27. Anisotropic nanoparticles: general discussion.

28. Particles at interfaces: general discussion.

29. Perceived deterrents to being a plasmapheresis donor in a voluntary, nonremunerated environment.

30. A prospective trial assessing the safety and efficacy of collecting up to 840 mL of plasma in conjunction with saline infusion during plasmapheresis.

31. Understanding the plasmapheresis donor in a voluntary, nonremunerated environment.

32. The granzyme B inhibitor, PI-9, is differentially expressed during placental development and up-regulated in hydatidiform moles.

33. Persistent familial hematuria in children and the locus for thin basement membrane nephropathy.

34. The high resolution crystal structure of the human tumor suppressor maspin reveals a novel conformational switch in the G-helix.

35. The genetics of thin basement membrane nephropathy.

36. Thin basement membrane nephropathy.

37. Clinical, histopathologic, and genetic studies in nine families with focal segmental glomerulosclerosis.

38. Mutations in the COL4A4 gene in thin basement membrane disease.

39. Perforin-independent expression of granzyme B and proteinase inhibitor 9 in human testis and placenta suggests a role for granzyme B-mediated proteolysis in reproduction.

40. A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome.

41. COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome.

42. Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1.

43. The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses.

44. Segregation of hematuria in thin basement membrane disease with haplotypes at the loci for Alport syndrome.

45. Haematuria in asymptomatic individuals.

46. Expression and purification of recombinant human granzyme B from Pichia pastoris.

Catalog

Books, media, physical & digital resources